Peter Gottlieb
Concepts (606)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 148 | 2026 | 3930 | 6.550 |
Why?
| | Insulin | 53 | 2026 | 2524 | 2.540 |
Why?
| | C-Peptide | 33 | 2026 | 191 | 2.010 |
Why?
| | Islets of Langerhans | 25 | 2026 | 852 | 1.880 |
Why?
| | Autoantibodies | 40 | 2026 | 1498 | 1.790 |
Why?
| | Hypoglycemic Agents | 23 | 2026 | 1411 | 1.560 |
Why?
| | Insulin-Secreting Cells | 18 | 2021 | 393 | 1.490 |
Why?
| | B-Lymphocytes | 10 | 2025 | 884 | 1.100 |
Why?
| | T-Lymphocytes | 25 | 2025 | 2007 | 0.940 |
Why?
| | Antilymphocyte Serum | 8 | 2021 | 55 | 0.930 |
Why?
| | Antibodies, Monoclonal, Humanized | 14 | 2026 | 992 | 0.920 |
Why?
| | CD4-Positive T-Lymphocytes | 14 | 2025 | 1148 | 0.900 |
Why?
| | Autoantigens | 15 | 2021 | 426 | 0.900 |
Why?
| | Monitoring, Ambulatory | 4 | 2010 | 88 | 0.890 |
Why?
| | Blood Glucose | 18 | 2026 | 2357 | 0.880 |
Why?
| | Autoimmunity | 19 | 2023 | 924 | 0.840 |
Why?
| | Proinsulin | 7 | 2024 | 54 | 0.750 |
Why?
| | Immunosuppressive Agents | 9 | 2023 | 824 | 0.740 |
Why?
| | Prediabetic State | 8 | 2026 | 250 | 0.740 |
Why?
| | Clinical Trials as Topic | 12 | 2025 | 1062 | 0.710 |
Why?
| | Adolescent | 79 | 2026 | 22451 | 0.680 |
Why?
| | Immunotherapy | 6 | 2025 | 669 | 0.630 |
Why?
| | Child | 72 | 2026 | 22638 | 0.630 |
Why?
| | Addison Disease | 8 | 2012 | 38 | 0.630 |
Why?
| | Adult | 96 | 2026 | 40821 | 0.630 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2010 | 704 | 0.620 |
Why?
| | Humans | 169 | 2026 | 145625 | 0.620 |
Why?
| | CD4 Antigens | 2 | 2013 | 135 | 0.590 |
Why?
| | Immunologic Factors | 7 | 2019 | 244 | 0.590 |
Why?
| | Preventive Medicine | 2 | 2018 | 38 | 0.570 |
Why?
| | Young Adult | 51 | 2026 | 14240 | 0.560 |
Why?
| | Polyendocrinopathies, Autoimmune | 3 | 2010 | 18 | 0.560 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2020 | 2623 | 0.540 |
Why?
| | Peptide Fragments | 13 | 2024 | 693 | 0.520 |
Why?
| | Insulin Antibodies | 6 | 2022 | 103 | 0.510 |
Why?
| | CD8-Positive T-Lymphocytes | 10 | 2019 | 929 | 0.500 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 171 | 0.490 |
Why?
| | Granulocyte Colony-Stimulating Factor | 6 | 2021 | 90 | 0.490 |
Why?
| | Mycophenolic Acid | 3 | 2012 | 117 | 0.460 |
Why?
| | Female | 98 | 2026 | 79080 | 0.450 |
Why?
| | Male | 90 | 2026 | 73014 | 0.440 |
Why?
| | Chromogranin A | 2 | 2024 | 43 | 0.440 |
Why?
| | Peptides | 5 | 2024 | 991 | 0.430 |
Why?
| | Monocytes | 4 | 2016 | 538 | 0.430 |
Why?
| | Steroid 21-Hydroxylase | 5 | 2012 | 27 | 0.430 |
Why?
| | Autoimmune Diseases | 10 | 2017 | 466 | 0.430 |
Why?
| | Immunoglobulin G | 6 | 2018 | 899 | 0.420 |
Why?
| | Glutamate Decarboxylase | 9 | 2022 | 166 | 0.420 |
Why?
| | Mice, Inbred NOD | 16 | 2023 | 598 | 0.420 |
Why?
| | Cytokines | 9 | 2018 | 2079 | 0.410 |
Why?
| | Biomarkers | 13 | 2024 | 4329 | 0.400 |
Why?
| | Vaccines, DNA | 1 | 2013 | 32 | 0.390 |
Why?
| | Cystic Fibrosis | 3 | 2012 | 1164 | 0.370 |
Why?
| | Interferon-gamma | 6 | 2021 | 780 | 0.370 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 104 | 0.370 |
Why?
| | Disease Progression | 17 | 2026 | 2857 | 0.370 |
Why?
| | T-Lymphocyte Subsets | 8 | 2018 | 415 | 0.370 |
Why?
| | Myeloid Cells | 1 | 2014 | 149 | 0.370 |
Why?
| | Immunomodulation | 1 | 2013 | 98 | 0.370 |
Why?
| | Immunologic Memory | 7 | 2019 | 369 | 0.360 |
Why?
| | Hypoglycemia | 6 | 2009 | 489 | 0.340 |
Why?
| | Genetic Predisposition to Disease | 11 | 2026 | 2455 | 0.330 |
Why?
| | Dendritic Cells | 2 | 2014 | 507 | 0.330 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 344 | 0.320 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2021 | 54 | 0.320 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 1101 | 0.300 |
Why?
| | Zinc Transporter 8 | 5 | 2026 | 70 | 0.300 |
Why?
| | CD3 Complex | 5 | 2019 | 112 | 0.300 |
Why?
| | Histocompatibility Antigens Class I | 6 | 2011 | 207 | 0.290 |
Why?
| | HLA-DR3 Antigen | 5 | 2022 | 76 | 0.290 |
Why?
| | Immunoconjugates | 4 | 2014 | 138 | 0.290 |
Why?
| | HLA-DR Antigens | 8 | 2018 | 211 | 0.290 |
Why?
| | Lymphocyte Activation | 7 | 2025 | 1136 | 0.290 |
Why?
| | Age of Onset | 7 | 2026 | 557 | 0.290 |
Why?
| | Area Under Curve | 9 | 2024 | 333 | 0.290 |
Why?
| | Hearing Aids | 2 | 2021 | 45 | 0.270 |
Why?
| | Glucose Tolerance Test | 7 | 2026 | 360 | 0.270 |
Why?
| | Antibodies, Monoclonal | 6 | 2010 | 1511 | 0.270 |
Why?
| | Clonal Anergy | 3 | 2018 | 55 | 0.270 |
Why?
| | Insulin, Regular, Human | 3 | 2024 | 47 | 0.260 |
Why?
| | Cation Transport Proteins | 3 | 2017 | 120 | 0.260 |
Why?
| | Toll-Like Receptors | 3 | 2014 | 193 | 0.250 |
Why?
| | Tympanic Membrane | 2 | 2017 | 21 | 0.240 |
Why?
| | Double-Blind Method | 12 | 2021 | 2064 | 0.230 |
Why?
| | Receptors, Interleukin-2 | 2 | 2006 | 64 | 0.230 |
Why?
| | Regeneration | 2 | 2017 | 198 | 0.230 |
Why?
| | Middle Aged | 38 | 2026 | 36359 | 0.230 |
Why?
| | Time Factors | 10 | 2020 | 7079 | 0.230 |
Why?
| | Animals | 34 | 2024 | 38030 | 0.230 |
Why?
| | Haplotypes | 7 | 2026 | 505 | 0.220 |
Why?
| | Child, Preschool | 22 | 2026 | 11888 | 0.220 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2026 | 2228 | 0.220 |
Why?
| | Protein Precursors | 3 | 2016 | 127 | 0.210 |
Why?
| | Insulin, Isophane | 1 | 2004 | 22 | 0.210 |
Why?
| | Antigen Presentation | 3 | 2018 | 209 | 0.210 |
Why?
| | Administration, Oral | 3 | 2026 | 867 | 0.200 |
Why?
| | Software | 2 | 2008 | 673 | 0.200 |
Why?
| | Mice | 26 | 2024 | 18266 | 0.200 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 3 | 2013 | 96 | 0.200 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2023 | 411 | 0.200 |
Why?
| | Precision Medicine | 3 | 2023 | 462 | 0.200 |
Why?
| | Temporal Bone | 2 | 2021 | 43 | 0.200 |
Why?
| | Treatment Outcome | 13 | 2026 | 11744 | 0.190 |
Why?
| | Pregnancy in Diabetics | 2 | 2003 | 123 | 0.190 |
Why?
| | Immunotherapy, Active | 2 | 2014 | 9 | 0.190 |
Why?
| | Plasmids | 4 | 2013 | 372 | 0.190 |
Why?
| | Diabetic Ketoacidosis | 2 | 2024 | 212 | 0.180 |
Why?
| | Polyethylene Glycols | 3 | 2018 | 649 | 0.180 |
Why?
| | Histocompatibility Testing | 4 | 2013 | 122 | 0.180 |
Why?
| | Interleukin-1beta | 3 | 2014 | 394 | 0.180 |
Why?
| | Epitopes, T-Lymphocyte | 4 | 2011 | 175 | 0.180 |
Why?
| | Body Weight | 2 | 2025 | 964 | 0.180 |
Why?
| | Lymphocyte Depletion | 2 | 2013 | 135 | 0.180 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2015 | 71 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell | 5 | 2022 | 676 | 0.170 |
Why?
| | Immune Tolerance | 2 | 2017 | 384 | 0.170 |
Why?
| | Methyldopa | 2 | 2019 | 6 | 0.170 |
Why?
| | Round Window, Ear | 1 | 2021 | 15 | 0.170 |
Why?
| | Recombinant Fusion Proteins | 2 | 2015 | 662 | 0.170 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 77 | 0.170 |
Why?
| | Necrobiosis Lipoidica | 1 | 2001 | 2 | 0.170 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 102 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2019 | 2018 | 0.160 |
Why?
| | Hyperglycemia | 1 | 2024 | 381 | 0.160 |
Why?
| | Histocompatibility Antigens Class II | 3 | 2011 | 365 | 0.160 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2001 | 85 | 0.160 |
Why?
| | History, 21st Century | 2 | 2018 | 224 | 0.160 |
Why?
| | Genotype | 7 | 2026 | 1866 | 0.160 |
Why?
| | History, 20th Century | 2 | 2018 | 330 | 0.150 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 11 | 0.150 |
Why?
| | Acoustic Stimulation | 1 | 2021 | 322 | 0.150 |
Why?
| | Biomarkers, Pharmacological | 1 | 2020 | 26 | 0.150 |
Why?
| | Biological Variation, Population | 1 | 2019 | 22 | 0.150 |
Why?
| | Cytomegalovirus | 2 | 2018 | 169 | 0.150 |
Why?
| | Hepatitis Delta Virus | 3 | 1994 | 7 | 0.150 |
Why?
| | Th2 Cells | 2 | 2014 | 179 | 0.150 |
Why?
| | Graves Disease | 2 | 2017 | 32 | 0.150 |
Why?
| | Epitopes | 5 | 2024 | 479 | 0.150 |
Why?
| | Luminescence | 2 | 2016 | 37 | 0.150 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 76 | 0.140 |
Why?
| | Mass Screening | 2 | 2025 | 1300 | 0.140 |
Why?
| | Hearing Loss | 1 | 2021 | 177 | 0.140 |
Why?
| | Forkhead Transcription Factors | 3 | 2016 | 208 | 0.140 |
Why?
| | Gastrointestinal Microbiome | 2 | 2018 | 767 | 0.140 |
Why?
| | Cytoprotection | 1 | 2018 | 55 | 0.140 |
Why?
| | Family | 3 | 2025 | 680 | 0.140 |
Why?
| | Viral Proteins | 3 | 1997 | 350 | 0.140 |
Why?
| | Homicide | 2 | 1990 | 65 | 0.140 |
Why?
| | Risk Factors | 14 | 2026 | 10840 | 0.140 |
Why?
| | Immunity, Cellular | 2 | 2018 | 277 | 0.130 |
Why?
| | Twins, Dizygotic | 1 | 2018 | 108 | 0.130 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2017 | 16 | 0.130 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 1990 | 198 | 0.130 |
Why?
| | HLA-A2 Antigen | 1 | 2017 | 36 | 0.130 |
Why?
| | Twins, Monozygotic | 1 | 2018 | 132 | 0.130 |
Why?
| | Biomedical Research | 2 | 2018 | 724 | 0.130 |
Why?
| | Abatacept | 5 | 2023 | 56 | 0.130 |
Why?
| | HLA-DR4 Antigen | 4 | 2022 | 74 | 0.130 |
Why?
| | HLA Antigens | 5 | 2026 | 241 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 358 | 0.130 |
Why?
| | Antibody-Producing Cells | 1 | 2017 | 30 | 0.130 |
Why?
| | Cell Separation | 2 | 2017 | 300 | 0.130 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2017 | 16 | 0.130 |
Why?
| | Thyroid Gland | 1 | 2017 | 93 | 0.130 |
Why?
| | Tympanic Membrane Perforation | 1 | 2017 | 15 | 0.130 |
Why?
| | Th1 Cells | 2 | 2009 | 138 | 0.130 |
Why?
| | Magnetic Fields | 1 | 2017 | 24 | 0.130 |
Why?
| | Follow-Up Studies | 9 | 2021 | 5397 | 0.120 |
Why?
| | Inflammation | 4 | 2018 | 2915 | 0.120 |
Why?
| | Dysbiosis | 1 | 2018 | 184 | 0.120 |
Why?
| | Antibody Formation | 1 | 2018 | 290 | 0.120 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 203 | 0.120 |
Why?
| | Trans-Activators | 1 | 1998 | 371 | 0.120 |
Why?
| | Influenza, Human | 1 | 2022 | 634 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2025 | 1754 | 0.120 |
Why?
| | RNA, Catalytic | 2 | 1994 | 191 | 0.120 |
Why?
| | Trypanosoma cruzi | 1 | 1995 | 38 | 0.110 |
Why?
| | Photochemotherapy | 1 | 1995 | 39 | 0.110 |
Why?
| | RNA, Viral | 5 | 1992 | 691 | 0.110 |
Why?
| | Tuftsin | 3 | 1983 | 4 | 0.110 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 366 | 0.110 |
Why?
| | Dermatologic Agents | 1 | 2015 | 69 | 0.110 |
Why?
| | Drug Therapy, Combination | 3 | 2018 | 1034 | 0.110 |
Why?
| | Genes, Viral | 4 | 1992 | 88 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 982 | 0.110 |
Why?
| | Homeodomain Proteins | 1 | 1998 | 525 | 0.110 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5875 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2022 | 330 | 0.100 |
Why?
| | Cochlear Implants | 1 | 2015 | 86 | 0.100 |
Why?
| | RNA, Double-Stranded | 3 | 1990 | 58 | 0.100 |
Why?
| | Phenotype | 2 | 2019 | 3186 | 0.100 |
Why?
| | Graft Rejection | 2 | 2015 | 504 | 0.100 |
Why?
| | Crime | 1 | 2014 | 58 | 0.100 |
Why?
| | Criminals | 1 | 2014 | 34 | 0.100 |
Why?
| | Law Enforcement | 1 | 2014 | 52 | 0.100 |
Why?
| | Withholding Treatment | 1 | 2013 | 77 | 0.100 |
Why?
| | Nanoparticles | 2 | 2017 | 521 | 0.100 |
Why?
| | Primary Cell Culture | 1 | 2013 | 172 | 0.100 |
Why?
| | Transglutaminases | 1 | 2013 | 137 | 0.090 |
Why?
| | Gene Expression | 2 | 2013 | 1461 | 0.090 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2013 | 224 | 0.090 |
Why?
| | Amino Acid Sequence | 10 | 2015 | 2088 | 0.090 |
Why?
| | Polymorphism, Genetic | 4 | 2010 | 611 | 0.090 |
Why?
| | DNA, Viral | 2 | 1994 | 352 | 0.090 |
Why?
| | Adjuvants, Immunologic | 1 | 2014 | 243 | 0.090 |
Why?
| | Nucleic Acid Conformation | 3 | 1994 | 723 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2009 | 3396 | 0.090 |
Why?
| | Adaptive Immunity | 1 | 2013 | 172 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 1992 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2014 | 165 | 0.090 |
Why?
| | Molecular Sequence Data | 11 | 2015 | 2835 | 0.090 |
Why?
| | Pancreatectomy | 1 | 2015 | 289 | 0.090 |
Why?
| | Receptors, Immunologic | 2 | 1983 | 210 | 0.090 |
Why?
| | Diabetic Angiopathies | 2 | 2010 | 265 | 0.090 |
Why?
| | Flow Cytometry | 4 | 2019 | 1160 | 0.090 |
Why?
| | Down-Regulation | 1 | 2014 | 612 | 0.090 |
Why?
| | RNA Phages | 2 | 1988 | 2 | 0.090 |
Why?
| | Thyroiditis | 1 | 1991 | 4 | 0.090 |
Why?
| | Alleles | 5 | 2011 | 900 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1318 | 0.080 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 147 | 0.080 |
Why?
| | Cells, Cultured | 7 | 2017 | 4112 | 0.080 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 102 | 0.080 |
Why?
| | Lymphocyte Count | 3 | 2019 | 166 | 0.080 |
Why?
| | Recombinant Proteins | 3 | 2018 | 1361 | 0.080 |
Why?
| | HLA-B Antigens | 1 | 2011 | 58 | 0.080 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 84 | 0.080 |
Why?
| | Interleukin-6 | 2 | 2012 | 782 | 0.080 |
Why?
| | Endocrine Cells | 1 | 2010 | 6 | 0.080 |
Why?
| | Prognosis | 5 | 2021 | 4331 | 0.080 |
Why?
| | Glycine | 1 | 2011 | 184 | 0.080 |
Why?
| | Cryopreservation | 1 | 2011 | 115 | 0.080 |
Why?
| | Transplantation Immunology | 1 | 1990 | 28 | 0.080 |
Why?
| | Pilot Projects | 3 | 2021 | 1878 | 0.080 |
Why?
| | Insulin, Long-Acting | 3 | 2004 | 65 | 0.080 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 377 | 0.080 |
Why?
| | Inflammation Mediators | 2 | 2010 | 507 | 0.080 |
Why?
| | Bacteriophages | 2 | 1990 | 110 | 0.080 |
Why?
| | Insulin Glargine | 3 | 2004 | 88 | 0.080 |
Why?
| | Herpesvirus 4, Human | 2 | 2026 | 172 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 845 | 0.070 |
Why?
| | Muromonab-CD3 | 1 | 2009 | 6 | 0.070 |
Why?
| | Bacteria | 1 | 2015 | 766 | 0.070 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 145 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2009 | 180 | 0.070 |
Why?
| | Single-Cell Analysis | 2 | 2025 | 366 | 0.070 |
Why?
| | Antigens | 3 | 2023 | 350 | 0.070 |
Why?
| | Receptors, Chemokine | 2 | 2007 | 47 | 0.070 |
Why?
| | Interleukin-17 | 1 | 2009 | 121 | 0.070 |
Why?
| | Calcinosis | 1 | 2010 | 231 | 0.070 |
Why?
| | Mental Health Services | 1 | 2014 | 449 | 0.070 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 188 | 0.070 |
Why?
| | Immunodominant Epitopes | 2 | 2006 | 27 | 0.070 |
Why?
| | Remission Induction | 2 | 2018 | 308 | 0.070 |
Why?
| | Platelet Membrane Glycoprotein IIb | 1 | 2007 | 4 | 0.060 |
Why?
| | Regression Analysis | 1 | 2010 | 994 | 0.060 |
Why?
| | Prisoners | 1 | 1990 | 146 | 0.060 |
Why?
| | Hydrocortisone | 2 | 2012 | 303 | 0.060 |
Why?
| | Enzyme-Linked Immunospot Assay | 3 | 2011 | 40 | 0.060 |
Why?
| | Insulin Infusion Systems | 2 | 2004 | 488 | 0.060 |
Why?
| | Mental Disorders | 2 | 2014 | 1133 | 0.060 |
Why?
| | Equipment Design | 1 | 2009 | 519 | 0.060 |
Why?
| | CD40 Antigens | 1 | 2007 | 67 | 0.060 |
Why?
| | Radioimmunoassay | 2 | 2017 | 162 | 0.060 |
Why?
| | Safety | 1 | 2009 | 346 | 0.060 |
Why?
| | Denmark | 3 | 2014 | 51 | 0.060 |
Why?
| | Case-Control Studies | 5 | 2016 | 3633 | 0.060 |
Why?
| | Risk Assessment | 3 | 2025 | 3678 | 0.060 |
Why?
| | Rituximab | 3 | 2013 | 208 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 159 | 0.060 |
Why?
| | Receptors, Interleukin-7 | 1 | 2006 | 28 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2010 | 410 | 0.060 |
Why?
| | Age Factors | 4 | 2017 | 3321 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2009 | 4565 | 0.060 |
Why?
| | Killer Cells, Natural | 2 | 2016 | 481 | 0.060 |
Why?
| | Mutation | 5 | 2015 | 4082 | 0.060 |
Why?
| | Base Sequence | 8 | 1994 | 2119 | 0.060 |
Why?
| | CD4 Lymphocyte Count | 3 | 2015 | 280 | 0.060 |
Why?
| | Hybridomas | 2 | 2004 | 233 | 0.060 |
Why?
| | Prospective Studies | 5 | 2026 | 8087 | 0.060 |
Why?
| | Isoenzymes | 2 | 2004 | 294 | 0.060 |
Why?
| | Proteins | 2 | 2018 | 1021 | 0.060 |
Why?
| | Disease Susceptibility | 2 | 2019 | 339 | 0.060 |
Why?
| | Infant | 5 | 2024 | 10093 | 0.060 |
Why?
| | Diabetic Retinopathy | 2 | 2005 | 211 | 0.060 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2004 | 166 | 0.050 |
Why?
| | Gene Frequency | 3 | 2016 | 495 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2005 | 68 | 0.050 |
Why?
| | Risk | 3 | 2019 | 917 | 0.050 |
Why?
| | Signal Transduction | 3 | 2019 | 5234 | 0.050 |
Why?
| | Acetamides | 1 | 2005 | 42 | 0.050 |
Why?
| | Major Histocompatibility Complex | 2 | 2002 | 233 | 0.050 |
Why?
| | Urban Population | 1 | 1988 | 496 | 0.050 |
Why?
| | Prevalence | 3 | 2024 | 2852 | 0.050 |
Why?
| | Exanthema | 2 | 2019 | 86 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 133 | 0.050 |
Why?
| | Capsid | 3 | 1990 | 94 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2018 | 324 | 0.050 |
Why?
| | Coronary Artery Disease | 1 | 2010 | 751 | 0.050 |
Why?
| | Immunoglobulin Fragments | 1 | 1983 | 11 | 0.050 |
Why?
| | Blood Coagulation Factors | 1 | 1984 | 71 | 0.050 |
Why?
| | Feces | 2 | 2018 | 494 | 0.050 |
Why?
| | Genes, MHC Class II | 2 | 2002 | 77 | 0.050 |
Why?
| | Placebos | 2 | 2013 | 190 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 372 | 0.050 |
Why?
| | Immunoassay | 1 | 2003 | 108 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 2 | 2019 | 585 | 0.050 |
Why?
| | Genetic Association Studies | 1 | 2025 | 376 | 0.050 |
Why?
| | Niacinamide | 1 | 2004 | 103 | 0.050 |
Why?
| | Cell Survival | 2 | 2019 | 1102 | 0.050 |
Why?
| | Tissue Donors | 1 | 2006 | 398 | 0.050 |
Why?
| | Interleukin-4 | 2 | 2002 | 207 | 0.050 |
Why?
| | Antigens, CD1 | 1 | 2002 | 59 | 0.050 |
Why?
| | Aged | 8 | 2026 | 26251 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2026 | 17291 | 0.050 |
Why?
| | Siblings | 2 | 2018 | 196 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2009 | 3121 | 0.040 |
Why?
| | Cloning, Molecular | 3 | 2014 | 526 | 0.040 |
Why?
| | Receptors, CXCR3 | 2 | 2016 | 17 | 0.040 |
Why?
| | Antibody Affinity | 2 | 2016 | 60 | 0.040 |
Why?
| | Diseases in Twins | 2 | 2018 | 114 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2009 | 1979 | 0.040 |
Why?
| | Canada | 2 | 2014 | 430 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2009 | 2497 | 0.040 |
Why?
| | Preconception Care | 1 | 2002 | 50 | 0.040 |
Why?
| | Reference Values | 3 | 2009 | 787 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2002 | 67 | 0.040 |
Why?
| | Pyrimidines | 1 | 2005 | 530 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2001 | 38 | 0.040 |
Why?
| | Pancreas | 2 | 2018 | 342 | 0.040 |
Why?
| | DNA | 4 | 1994 | 1418 | 0.040 |
Why?
| | Administration, Topical | 1 | 2001 | 153 | 0.040 |
Why?
| | Venoms | 1 | 2020 | 22 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1843 | 0.040 |
Why?
| | Kinetics | 4 | 1994 | 1553 | 0.040 |
Why?
| | Vitamin D | 1 | 2004 | 402 | 0.040 |
Why?
| | Rats, Inbred BB | 2 | 1991 | 5 | 0.040 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2020 | 15 | 0.040 |
Why?
| | HLA-DR2 Antigen | 1 | 1999 | 8 | 0.040 |
Why?
| | Membrane Proteins | 2 | 2004 | 1130 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2019 | 77 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 1999 | 12 | 0.040 |
Why?
| | Bacterial Proteins | 2 | 2018 | 976 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 379 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 727 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3 | 2007 | 44 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2003 | 502 | 0.040 |
Why?
| | Interleukin-7 | 1 | 2019 | 66 | 0.040 |
Why?
| | HLA-DRB1 Chains | 3 | 2009 | 109 | 0.040 |
Why?
| | Pseudomonas | 2 | 1990 | 30 | 0.040 |
Why?
| | HLA-A Antigens | 2 | 2011 | 52 | 0.040 |
Why?
| | Mice, Inbred BALB C | 4 | 2011 | 1244 | 0.040 |
Why?
| | CD4-CD8 Ratio | 1 | 2019 | 23 | 0.040 |
Why?
| | ROC Curve | 1 | 2021 | 613 | 0.040 |
Why?
| | Lymphopenia | 1 | 2019 | 62 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 538 | 0.040 |
Why?
| | Leg | 1 | 2001 | 243 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 241 | 0.040 |
Why?
| | Hemorrhage | 1 | 1984 | 824 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 377 | 0.030 |
Why?
| | Databases, Factual | 1 | 2004 | 1481 | 0.030 |
Why?
| | Meals | 1 | 2020 | 130 | 0.030 |
Why?
| | Seroconversion | 1 | 2018 | 48 | 0.030 |
Why?
| | Insulin Lispro | 3 | 2004 | 44 | 0.030 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2018 | 39 | 0.030 |
Why?
| | Therapies, Investigational | 1 | 2018 | 18 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2018 | 13 | 0.030 |
Why?
| | B7-2 Antigen | 1 | 2017 | 27 | 0.030 |
Why?
| | Macrophages | 2 | 1983 | 1530 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2018 | 169 | 0.030 |
Why?
| | Wound Healing | 1 | 2001 | 348 | 0.030 |
Why?
| | Ikaros Transcription Factor | 1 | 2018 | 23 | 0.030 |
Why?
| | Cell Death | 1 | 2019 | 379 | 0.030 |
Why?
| | Colorado | 2 | 2024 | 4588 | 0.030 |
Why?
| | Glucose | 1 | 2023 | 1051 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2018 | 2131 | 0.030 |
Why?
| | Twins | 1 | 2018 | 156 | 0.030 |
Why?
| | Rats | 3 | 1991 | 5574 | 0.030 |
Why?
| | Drug Discovery | 1 | 2018 | 153 | 0.030 |
Why?
| | Genetic Markers | 1 | 1998 | 337 | 0.030 |
Why?
| | Structure-Activity Relationship | 2 | 2011 | 561 | 0.030 |
Why?
| | Clone Cells | 3 | 2004 | 259 | 0.030 |
Why?
| | Gene Expression Regulation | 3 | 2014 | 2591 | 0.030 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2016 | 26 | 0.030 |
Why?
| | Patient Care Planning | 1 | 2018 | 170 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2016 | 34 | 0.030 |
Why?
| | Luminescent Measurements | 1 | 2017 | 75 | 0.030 |
Why?
| | Environment | 1 | 2018 | 295 | 0.030 |
Why?
| | Antigens, CD | 2 | 2014 | 559 | 0.030 |
Why?
| | HLA-DQ beta-Chains | 2 | 2009 | 58 | 0.030 |
Why?
| | Influenza A virus | 1 | 1997 | 120 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2016 | 77 | 0.030 |
Why?
| | Leukocyte Common Antigens | 2 | 2007 | 86 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 315 | 0.030 |
Why?
| | United States | 4 | 2015 | 16041 | 0.030 |
Why?
| | Somalia | 1 | 2016 | 7 | 0.030 |
Why?
| | Antibody Specificity | 2 | 2007 | 181 | 0.030 |
Why?
| | Isoindoles | 1 | 1995 | 5 | 0.030 |
Why?
| | Forecasting | 1 | 1998 | 386 | 0.030 |
Why?
| | Parasitemia | 1 | 1995 | 15 | 0.030 |
Why?
| | Orphan Drug Production | 1 | 2015 | 5 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 2097 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 306 | 0.030 |
Why?
| | Radiation-Sensitizing Agents | 1 | 1995 | 43 | 0.030 |
Why?
| | Coloring Agents | 1 | 1995 | 88 | 0.030 |
Why?
| | Minnesota | 1 | 2016 | 167 | 0.030 |
Why?
| | Cities | 1 | 2016 | 140 | 0.030 |
Why?
| | Transfusion Reaction | 1 | 1995 | 61 | 0.030 |
Why?
| | Intestines | 1 | 2018 | 351 | 0.030 |
Why?
| | Chagas Disease | 1 | 1995 | 41 | 0.030 |
Why?
| | Cohort Studies | 3 | 2015 | 6045 | 0.030 |
Why?
| | Immunity, Humoral | 1 | 2016 | 121 | 0.030 |
Why?
| | Ethics, Medical | 1 | 2015 | 90 | 0.030 |
Why?
| | Immunity, Active | 1 | 2014 | 8 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2015 | 249 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 382 | 0.030 |
Why?
| | Transcription, Genetic | 4 | 1994 | 1429 | 0.030 |
Why?
| | Proline | 1 | 1994 | 79 | 0.030 |
Why?
| | Immunity, Innate | 2 | 2009 | 843 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2014 | 162 | 0.030 |
Why?
| | Opportunistic Infections | 1 | 2014 | 47 | 0.030 |
Why?
| | Immunoglobulin Idiotypes | 1 | 1993 | 28 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2014 | 312 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1995 | 1041 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2015 | 303 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 1994 | 357 | 0.020 |
Why?
| | Sequence Deletion | 1 | 1994 | 190 | 0.020 |
Why?
| | Drug Combinations | 1 | 2014 | 399 | 0.020 |
Why?
| | Europe | 1 | 2014 | 420 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2013 | 39 | 0.020 |
Why?
| | Prosthesis Design | 1 | 2015 | 357 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2015 | 310 | 0.020 |
Why?
| | Polymerase Chain Reaction | 3 | 2009 | 1030 | 0.020 |
Why?
| | Mutagenesis | 1 | 1994 | 196 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 507 | 0.020 |
Why?
| | Cost of Illness | 1 | 2015 | 322 | 0.020 |
Why?
| | Formamides | 1 | 1992 | 8 | 0.020 |
Why?
| | Escherichia coli Proteins | 1 | 1994 | 200 | 0.020 |
Why?
| | Herpesviridae | 1 | 2012 | 21 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2014 | 201 | 0.020 |
Why?
| | Virus Replication | 3 | 1997 | 525 | 0.020 |
Why?
| | Body Mass Index | 1 | 2021 | 2446 | 0.020 |
Why?
| | Interleukins | 1 | 2014 | 247 | 0.020 |
Why?
| | Mice, Inbred Strains | 2 | 1993 | 384 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 1997 | 541 | 0.020 |
Why?
| | Graft Survival | 1 | 2015 | 508 | 0.020 |
Why?
| | Renin | 1 | 2012 | 33 | 0.020 |
Why?
| | Postprandial Period | 1 | 2013 | 114 | 0.020 |
Why?
| | Pregnancy | 2 | 2003 | 7217 | 0.020 |
Why?
| | RNA, Antisense | 1 | 1992 | 18 | 0.020 |
Why?
| | Lymph Nodes | 2 | 2006 | 511 | 0.020 |
Why?
| | Virus Activation | 1 | 2012 | 97 | 0.020 |
Why?
| | Ligands | 2 | 2005 | 676 | 0.020 |
Why?
| | Indoles | 1 | 1995 | 509 | 0.020 |
Why?
| | HLA-B15 Antigen | 1 | 2011 | 12 | 0.020 |
Why?
| | Phagocytosis | 2 | 1983 | 298 | 0.020 |
Why?
| | Sample Size | 1 | 2011 | 123 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1202 | 0.020 |
Why?
| | Thallium Radioisotopes | 1 | 1991 | 8 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2015 | 547 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 901 | 0.020 |
Why?
| | Viral Core Proteins | 1 | 1990 | 21 | 0.020 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 16 | 0.020 |
Why?
| | Receptors, Cell Surface | 2 | 1983 | 371 | 0.020 |
Why?
| | RNA Splicing | 1 | 1992 | 287 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1824 | 0.020 |
Why?
| | HLA-B8 Antigen | 1 | 2010 | 11 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 113 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 54 | 0.020 |
Why?
| | Isoantigens | 1 | 1990 | 17 | 0.020 |
Why?
| | Amino Acid Substitution | 2 | 2002 | 295 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 1990 | 316 | 0.020 |
Why?
| | Spleen | 3 | 2002 | 503 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 257 | 0.020 |
Why?
| | RNA Viruses | 1 | 1990 | 75 | 0.020 |
Why?
| | Chemokines | 1 | 2010 | 217 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 409 | 0.020 |
Why?
| | Homozygote | 1 | 2009 | 196 | 0.020 |
Why?
| | Pedigree | 1 | 2010 | 507 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 294 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2009 | 244 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 1990 | 415 | 0.020 |
Why?
| | Nausea | 1 | 2009 | 111 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 2112 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 3005 | 0.020 |
Why?
| | Vomiting | 1 | 2009 | 131 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2009 | 284 | 0.020 |
Why?
| | Coronary Disease | 1 | 1991 | 380 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2009 | 201 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 1988 | 72 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2009 | 326 | 0.020 |
Why?
| | Cell Line | 2 | 2004 | 2809 | 0.020 |
Why?
| | Codon | 1 | 1988 | 92 | 0.020 |
Why?
| | Exercise Test | 1 | 1991 | 634 | 0.020 |
Why?
| | DNA Methylation | 1 | 2013 | 721 | 0.020 |
Why?
| | Fever | 1 | 2009 | 320 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 840 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1988 | 384 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 1994 | 1467 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1991 | 356 | 0.020 |
Why?
| | Life Style | 1 | 1990 | 495 | 0.020 |
Why?
| | Antisocial Personality Disorder | 1 | 1988 | 123 | 0.020 |
Why?
| | Morphogenesis | 1 | 1988 | 163 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 220 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 82 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 395 | 0.020 |
Why?
| | NF-kappa B | 1 | 2010 | 674 | 0.020 |
Why?
| | Models, Molecular | 1 | 2011 | 1571 | 0.010 |
Why?
| | Chromogranins | 1 | 2006 | 13 | 0.010 |
Why?
| | Social Environment | 1 | 1988 | 246 | 0.010 |
Why?
| | Suicide, Attempted | 1 | 1990 | 374 | 0.010 |
Why?
| | Phosphorylation | 1 | 2010 | 1717 | 0.010 |
Why?
| | Keratins | 1 | 2006 | 57 | 0.010 |
Why?
| | Mice, Inbred C3H | 2 | 1983 | 252 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 751 | 0.010 |
Why?
| | Hemodynamics | 1 | 1991 | 1114 | 0.010 |
Why?
| | Psychotic Disorders | 1 | 1988 | 181 | 0.010 |
Why?
| | Chemokine CXCL11 | 1 | 2005 | 3 | 0.010 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 13 | 0.010 |
Why?
| | Thyroglobulin | 1 | 2005 | 28 | 0.010 |
Why?
| | Alprostadil | 1 | 2005 | 29 | 0.010 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 34 | 0.010 |
Why?
| | Glucagon | 1 | 2006 | 114 | 0.010 |
Why?
| | Chemokine CXCL9 | 1 | 2005 | 38 | 0.010 |
Why?
| | Chemokine CXCL10 | 1 | 2005 | 39 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2011 | 6021 | 0.010 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 1984 | 6 | 0.010 |
Why?
| | Interpersonal Relations | 1 | 1988 | 387 | 0.010 |
Why?
| | Fathers | 1 | 2005 | 53 | 0.010 |
Why?
| | Antigenic Variation | 1 | 2004 | 12 | 0.010 |
Why?
| | Dinoprostone | 1 | 2005 | 179 | 0.010 |
Why?
| | Mice, Inbred CBA | 1 | 2004 | 56 | 0.010 |
Why?
| | Tetanus Toxin | 1 | 2003 | 6 | 0.010 |
Why?
| | Chaperonin 60 | 1 | 2003 | 11 | 0.010 |
Why?
| | Infusion Pumps, Implantable | 1 | 2004 | 26 | 0.010 |
Why?
| | Insulin Aspart | 1 | 2004 | 30 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2004 | 170 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 1983 | 105 | 0.010 |
Why?
| | Escherichia coli | 1 | 1988 | 831 | 0.010 |
Why?
| | Homeostasis | 1 | 2007 | 646 | 0.010 |
Why?
| | Fibrosis | 1 | 2006 | 568 | 0.010 |
Why?
| | Quality of Life | 1 | 2015 | 3187 | 0.010 |
Why?
| | Biological Assay | 1 | 1983 | 133 | 0.010 |
Why?
| | Fetal Macrosomia | 1 | 2003 | 63 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1983 | 185 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2004 | 434 | 0.010 |
Why?
| | Models, Biological | 1 | 1990 | 1758 | 0.010 |
Why?
| | Antigens, CD1d | 1 | 2002 | 69 | 0.010 |
Why?
| | C-Reactive Protein | 1 | 2005 | 427 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 782 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 735 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 75 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2002 | 155 | 0.010 |
Why?
| | Congenital Abnormalities | 1 | 2003 | 108 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2010 | 1247 | 0.010 |
Why?
| | Albuminuria | 1 | 2003 | 190 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2015 | 2962 | 0.010 |
Why?
| | Temperature | 2 | 1997 | 633 | 0.010 |
Why?
| | Sex Factors | 1 | 1988 | 2101 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1709 | 0.010 |
Why?
| | Celiac Disease | 1 | 2005 | 285 | 0.010 |
Why?
| | CTLA-4 Antigen | 1 | 2002 | 105 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1531 | 0.010 |
Why?
| | Alcoholism | 1 | 1988 | 830 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 1999 | 17 | 0.010 |
Why?
| | Birth Weight | 1 | 2003 | 521 | 0.010 |
Why?
| | Glutamine | 1 | 2000 | 110 | 0.010 |
Why?
| | Gestational Age | 1 | 2003 | 989 | 0.010 |
Why?
| | DNA-Directed RNA Polymerases | 2 | 1990 | 60 | 0.010 |
Why?
| | Alanine | 1 | 2000 | 171 | 0.010 |
Why?
| | Mothers | 1 | 2005 | 771 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 1988 | 1098 | 0.010 |
Why?
| | Aging | 2 | 2007 | 1983 | 0.010 |
Why?
| | Incidence | 1 | 2005 | 2910 | 0.010 |
Why?
| | Mesocricetus | 1 | 1997 | 47 | 0.010 |
Why?
| | Chickens | 1 | 1997 | 169 | 0.010 |
Why?
| | Cricetinae | 1 | 1997 | 295 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 3538 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1997 | 129 | 0.010 |
Why?
| | Trifluoroethanol | 1 | 1994 | 1 | 0.010 |
Why?
| | Transfection | 1 | 1997 | 914 | 0.010 |
Why?
| | Polydeoxyribonucleotides | 1 | 1994 | 14 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1994 | 26 | 0.010 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 1994 | 25 | 0.010 |
Why?
| | Survival Rate | 1 | 1999 | 2078 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1994 | 149 | 0.010 |
Why?
| | p-Azobenzenearsonate | 1 | 1993 | 5 | 0.010 |
Why?
| | Genes, Immunoglobulin | 1 | 1993 | 29 | 0.010 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 1993 | 22 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 1994 | 117 | 0.010 |
Why?
| | Immunoglobulin Variable Region | 1 | 1993 | 78 | 0.010 |
Why?
| | Cross Reactions | 1 | 1993 | 129 | 0.010 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 1993 | 83 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 326 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1990 | 80 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1991 | 116 | 0.010 |
Why?
| | Computer Simulation | 1 | 1994 | 1014 | 0.000 |
Why?
| | Genome, Viral | 1 | 1992 | 217 | 0.000 |
Why?
| | Neoplasms | 1 | 1983 | 2944 | 0.000 |
Why?
| | Lethal Dose 50 | 1 | 1983 | 17 | 0.000 |
Why?
| | Fibrosarcoma | 1 | 1983 | 22 | 0.000 |
Why?
| | Leukocytosis | 1 | 1983 | 31 | 0.000 |
Why?
| | Neoplasm Transplantation | 1 | 1983 | 238 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1983 | 319 | 0.000 |
Why?
| | Hypertension | 1 | 1991 | 1270 | 0.000 |
Why?
| | Dogs | 1 | 1983 | 516 | 0.000 |
Why?
|
|
Gottlieb's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|